A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Clinical trial NCT01983501 · COMPLETED

Trial details

NCT number: NCT01983501
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2 Positive Breast Cancers

Start date: 2014-02-28
Primary completion: 2017-10-10
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.